- Home
- MPW
MPW
Medical Properties Trust Inc. common stock
as 04-18-2025 1:39pm EST
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | BIRMINGHAM |
| Market Cap: | N/A | IPO Year: | 2005 |
| Target Price: | $5.64 | AVG Volume (30 days): | 11.3M |
| Analyst Decision: | Hold | Number of Analysts: | 7 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | -4.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.51 - $6.55 | Next Earning Date: | 05-08-2025 |
| Revenue: | $1,038,695,000 | Revenue Growth: | 17.27% |
| Revenue Growth (this year): | -9.78% | Revenue Growth (next year): | 7.78% |
Stock Insider Trading Activity of Medical Properties Trust Inc. common stock (MPW)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hanna James Kevin | MPW | Senior VP, Controller & CAO | Mar 5 '25 | Buy | $5.75 | 7,411 | $42,613.25 | 372,338 |
Latest Medical Properties Trust Inc. common stock News
MPW Breaking Stock News: Dive into MPW Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Medical Properties (MPW) Surpasses Market Returns: Some Facts Worth Knowing
Argus Research
4 days ago
MPW: Rating increased to a BUY
Zacks
5 days ago
Medical Properties (MPW) Laps the Stock Market: Here's Why
Motley Fool
8 days ago
These 2 Dividend Stocks Are Defying the Market Correction -- Are They Buys?
Zacks
9 days ago
Strength Seen in Brookfield Infrastructure (BIP): Can Its 8.8% Jump Turn into More Strength?
Zacks
10 days ago
How to Boost Your Portfolio with Top Finance Stocks Set to Beat Earnings
Argus Research
11 days ago
MPW: Lowering target price to $5.00
Zacks
12 days ago
Medical Properties Trust, Inc. (MPW) Is a Trending Stock: Facts to Know Before Betting on It
Compare MPW vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MPW Medical Properties Trust Inc. common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.